Haemonetics Co. (NYSE:HAE) Director Pedro P. Granadillo sold 12,322 shares of the business’s stock in a transaction on Thursday, November 8th. The stock was sold at an average price of $114.50, for a total transaction of $1,410,869.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Pedro P. Granadillo also recently made the following trade(s):
- On Monday, September 17th, Pedro P. Granadillo sold 30,824 shares of Haemonetics stock. The stock was sold at an average price of $111.83, for a total transaction of $3,447,047.92.
HAE traded down $3.53 during trading on Friday, reaching $111.55. 41,283 shares of the stock traded hands, compared to its average volume of 462,794. The company has a current ratio of 2.92, a quick ratio of 1.94 and a debt-to-equity ratio of 0.47. The stock has a market capitalization of $5.62 billion, a P/E ratio of 59.85, a price-to-earnings-growth ratio of 3.52 and a beta of 1.09. Haemonetics Co. has a 12 month low of $52.88 and a 12 month high of $117.56.
Several analysts recently weighed in on HAE shares. Zacks Investment Research raised shares of Haemonetics from a “hold” rating to a “strong-buy” rating and set a $122.00 price objective on the stock in a research note on Friday, October 12th. Barrington Research reissued a “buy” rating and issued a $127.00 price objective on shares of Haemonetics in a research note on Friday, October 5th. Morgan Stanley boosted their price objective on shares of Haemonetics from $100.00 to $120.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 8th. Jefferies Financial Group reissued a “buy” rating and issued a $125.00 price objective on shares of Haemonetics in a research note on Tuesday, August 7th. Finally, TheStreet cut shares of Haemonetics from a “b” rating to a “c+” rating in a research note on Monday, August 20th. One equities research analyst has rated the stock with a hold rating, four have issued a buy rating and two have issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $113.20.
Institutional investors and hedge funds have recently modified their holdings of the business. Chicago Equity Partners LLC boosted its position in Haemonetics by 34.0% during the second quarter. Chicago Equity Partners LLC now owns 86,665 shares of the medical instruments supplier’s stock valued at $7,772,000 after acquiring an additional 22,000 shares during the last quarter. Liberty Mutual Group Asset Management Inc. bought a new stake in Haemonetics during the second quarter valued at $932,000. ING Groep NV bought a new stake in Haemonetics during the second quarter valued at $485,000. MetLife Investment Advisors LLC boosted its position in Haemonetics by 142.0% during the second quarter. MetLife Investment Advisors LLC now owns 57,955 shares of the medical instruments supplier’s stock valued at $5,197,000 after acquiring an additional 34,009 shares during the last quarter. Finally, Boston Partners bought a new stake in Haemonetics during the second quarter valued at $1,794,000. 96.44% of the stock is currently owned by institutional investors and hedge funds.
Haemonetics Company Profile
Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.